Ionis' lipid-lowering drug hits phase 3 goal, raising hopes in untapped rare disease market

Ionis Pharmaceuticals' phase 3 lipid-lowering clinical trial has hit its primary endpoint, positioning it to file for an approval that would set up the company's first independent commercial launch. The study linked the high dose to a significant reduction in triglyceride levels and a 100% drop in acute pancreatitis events compared to placebo.